Goldstein Julie Ann

SEC source: 0001493152-26-042149 · ownership.xml · nonDerivative · entry 1

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,510

F1 · shares: Annual Deferred Stock Units award which vests in 12 equal monthly installments from the grant date; provided, however, that the Deferred Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting following the grant date, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person (RP) remains in continuous service with the Issuer or an affiliate through the applicable vesting date.

F2 · balance_after: Includes 29,011 shares that have vested pursuant to previously issued Deferred Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant.

F3 · balance_after: Includes 1,665 shares held in NeuroSpine Ventures; an entity in which the RP has no voting or dispositive power over the shares. Accordingly, the RP disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001641172-25-026578 · ownership.xml · nonDerivative · entry 1

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,387

F1 · shares: Annual Deferred Stock Units award which vests in 12 equal monthly installments from the grant date; provided, however, that the Deferred Stock Units shall vest in full on the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting following the grant date, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person (RP) remains in continuous service with the Issuer or an affiliate through the applicable vesting date.

F2 · balance_after: Includes 10,000 shares that have vested pursuant to previously issued Deferred Stock Units. All such vested shares were previously reported on Form 4 filings at the time of grant.

F3 · balance_after: Includes 1,665 shares held in NeuroSpine Ventures; an entity in which the RP has no voting or dispositive power over the shares. Accordingly, the RP disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001193805-24-001096 · e663872_4-goldstein.xml · derivative · entry 1

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,845

Underlying: Common Stock · 19,845 shares

Expires 2034-09-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments from the grant date; provided, however, that the option shall become fully vested and exercisable on the date that is the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting following the grant date, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date.

SEC source: 0001193805-24-000757 · e663688_4-goldstein.xml · derivative · entry 2

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,850

Underlying: Common Stock · 3,850 shares

Expires 2029-06-05

F1 · kind: On June 5, 2024, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 7,701 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase one-half share of the Issuer's Common Stock. The combined purchase price in the Offering was $6.4925 per Unit, inclusive of $6.43 per share of Common Stock and $0.0625 per Warrant. Each Warrant entitles the holder thereof to purchase one half of a share of Common Stock, is immediately exercisable from the date of issuance at an exercise price of $6.43 per share, and expires five years after issuance.

SEC source: 0001193805-24-000757 · e663688_4-goldstein.xml · nonDerivative · entry 1

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,380

F1 · shares: On June 5, 2024, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 7,701 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase one-half share of the Issuer's Common Stock. The combined purchase price in the Offering was $6.4925 per Unit, inclusive of $6.43 per share of Common Stock and $0.0625 per Warrant. Each Warrant entitles the holder thereof to purchase one half of a share of Common Stock, is immediately exercisable from the date of issuance at an exercise price of $6.43 per share, and expires five years after issuance.

F2 · balance_after: Includes 7,500 shares that have vested pursuant to previously issued Deferred Stock Units; 2,500 of such shares will vest monthly through March 15, 2025, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date. All such vested and unvested shares were previously reported on Form 4 filings at the time of grant.

F3 · balance_after: Includes 1,665 shares held in NeuroSpine Ventures; an entity in which the Reporting Person has no voting or dispositive power over the shares. Accordingly, the Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001193805-23-001124 · e618854_4-goldstein.xml · derivative · entry 1

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,989

Underlying: Common Stock · 25,989 shares

Expires 2033-08-08

F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments from the grant date; provided, however, that the option shall become fully vested and exercisable on the date that is the earlier of (i) the close of business one business day prior to the Issuer's next annual stockholder meeting on or after January 1, 2024, and (ii) the date immediately prior to a change of control, in each case, provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date.

SEC source: 0001193805-23-001088 · e618834_4-goldstein.xml · derivative · entry 2

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,997

Underlying: Common Stock · 16,997 shares

Expires 2029-02-02

F1 · kind: On August 2, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 33,994 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase one-half share of the Issuer's Common Stock. The combined purchase price in the Offering was $4.4125 per Unit, inclusive of $4.35 per share of Common Stock and $0.0625 per Warrant. Each Warrant entitles the holder thereof to purchase one half of a share of Common Stock, is exercisable beginning six months from the date of issuance at an exercise price of $4.35 per share, and expires five years from the initial exercise date.

SEC source: 0001193805-23-001088 · e618834_4-goldstein.xml · nonDerivative · entry 1

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,679

F1 · shares: On August 2, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 33,994 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase one-half share of the Issuer's Common Stock. The combined purchase price in the Offering was $4.4125 per Unit, inclusive of $4.35 per share of Common Stock and $0.0625 per Warrant. Each Warrant entitles the holder thereof to purchase one half of a share of Common Stock, is exercisable beginning six months from the date of issuance at an exercise price of $4.35 per share, and expires five years from the initial exercise date.

F2 · balance_after: Includes 4,444 shares that have vested pursuant to previously issued Deferred Stock Units; 5,556 of shares will vest monthly through March 15, 2025. All such vested and unvested shares were previously reported on Form 4 filings at the time of grant.

F3 · balance_after: Includes 1,665 shares held in NeuroSpine Ventures; an entity in which the Reporting Person has no voting or dispositive power over the shares. Accordingly, the Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001193805-22-000867 · e621697_4-goldstein.xml · nonDerivative · entry 1

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 460,212

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.39 to $0.40 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by him at each separate price on May 23, 2022.

F2 · balance_after: Excludes 150,000 shares issuable pursuant to previously reported deferred stock units.

SEC source: 0001193805-22-000516 · e621466_4-goldstein.xml · nonDerivative · entry 1

Goldstein Julie Ann · CIK 0001917358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 510,212

F1 · shares: The deferred stock units vest (i) in 36 equal monthly increments over a period of 36 months from the grant date, and (ii) in full on the date immediately prior to a change of control, in each case provided that the Reporting Person remains in continuous service with the Issuer or an affiliate through the applicable vesting date.